drugset
Drugs / Anvumetostat
last change Mar 2026 re-read 9 days ago

Anvumetostat

targets PRMT5 via inhibition

Developed for
non-small cell lung carcinoma · digestive system carcinoma
Investigated by
Amgen

Trials 5

today NCT06593522 · Ph 2 NCT06333951 · Ph 1 NCT06360354 · Ph 1 NCT05975073 · Ph 1/2 NCT05094336 · Ph 1/2
202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06333951 Sep 2024 → Oct 2026 expected non-small cell lung carcinoma Amgen Active not recruiting No outcome recorded
Phase 1 NCT06360354 May 2024 → Oct 2026 expected digestive system carcinoma Amgen Active not recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05975073 Aug 2023 → Feb 2026 non-small cell lung carcinoma Amgen Completed No outcome recorded
Phase 1/2 NCT05094336 Feb 2022 → Nov 2026 expected — Amgen Active not recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT06593522 Dec 2024 → Oct 2026 expected — Amgen Active not recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as anvumetostat ClinicalTrials.gov intervention name — accepted as the source's own label NCT06593522 ↗
4

NCT06333951 ↗

NCT05094336 ↗

NCT05975073 ↗

NCT06360354 ↗
Action Inhibit “MTA Cooperative PRMT5 inhibitor” NCT05094336 ↗
Route Oral “Anvumetostat: Orally via tablet” NCT05094336 ↗
Target PRMT5 “MTA Cooperative PRMT5 inhibitor” NCT05094336 ↗